Press Releases Toleranzia AB

Equities

Delayed Nasdaq Stockholm Other stock markets 14:11:35 14/05/2024 BST			5-day change	1st Jan Change
0.528 ^SEK	-1.49%		-2.22%	+23.36%

02-23	Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
02-23	Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Toleranzia AB: Annual report for the financial year 2023	04-30	AQ
Toleranzia AB receives loan commitment of SEK 20 million	04-24	AQ
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	03-18	AQ
Toleranzia AB – Year-End Report 2023	02-23	AQ
Toleranzia successfully completes GLP toxicology study of TOL2	01-15	AQ
Toleranzia AB starts production of finished drug product for clinical studies	12-21	AQ
Toleranzia AB presents Nomination Committee	12-15	AQ
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency	12-06	AQ
Toleranzia AB: Interim report third quarter 2023	27/10/23	AQ
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer	16/10/23	AQ
Toleranzia starts toxicology study of its lead drug candidate TOL2	26/09/23	AQ
Toleranzia announces outcome in rights issue	15/09/23	AQ
Toleranzia publishes prospectus in connection with rights issue of units	28/08/23	AQ
Toleranzia AB: Interim report second quarter 2023	25/08/23	AQ
Toleranzia establishes a freeze-dried formulation of the TOL2 drug product	24/08/23	AQ
Toleranzia runs GMP manufacturing of drug candidate TOL2 for clinical study	21/08/23	AQ
Toleranzia carries out a rights issue of units of approximately SEK 55 million	18/08/23	AQ
Announcement from the 2023 Annual General Meeting of Toleranzia AB (publ)	07/06/23	AQ
Notice of Annual General Meeting of Toleranzia AB (publ)	09/05/23	AQ
Toleranzia AB: Interim report 2023-01-01 – 2023-03-31	03/05/23	AQ

No results for this search